Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

BioLine RX stock price, quote, forecast and news

BLRX.TA
IL0011015182

Price

4.58
Today +/-
+0.09
Today %
+2.28 %
P

BioLine RX stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the BioLine RX stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the BioLine RX stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the BioLine RX stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze BioLine RX's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

BioLine RX Stock Price History

DateBioLine RX Price
9/12/20244.58 undefined
9/11/20244.48 undefined
9/10/20244.49 undefined
9/9/20244.37 undefined
9/8/20244.39 undefined
9/5/20244.57 undefined
9/4/20244.57 undefined
9/3/20244.52 undefined
9/2/20244.78 undefined
9/1/20244.67 undefined
8/29/20244.59 undefined
8/28/20244.89 undefined
8/27/20244.92 undefined
8/26/20245.03 undefined
8/25/20245.06 undefined
8/22/20245.04 undefined
8/21/20245.03 undefined
8/20/20245.08 undefined
8/19/20245.11 undefined
8/18/20245.14 undefined

BioLine RX Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BioLine RX, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioLine RX from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioLine RX’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BioLine RX. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BioLine RX’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BioLine RX’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioLine RX’s growth potential.

BioLine RX Revenue, EBIT and net profit per share

DateBioLine RX RevenueBioLine RX EBITBioLine RX Net Income
20234.8 M undefined-42.99 M undefined-60.61 M undefined
20220 undefined-29.16 M undefined-24.95 M undefined
20210 undefined-24.78 M undefined-27.05 M undefined
20200 undefined-22.93 M undefined-30.02 M undefined
20190 undefined-28.11 M undefined-25.45 M undefined
20180 undefined-25.61 M undefined-22.96 M undefined
20170 undefined-25.24 M undefined-24.35 M undefined
20160 undefined-16.51 M undefined-15.84 M undefined
20150 undefined-16.2 M undefined-14.4 M undefined
20140 undefined-17.16 M undefined-11.09 M undefined
20130 undefined-16.99 M undefined-17.04 M undefined
20120 undefined-21.19 M undefined-19.81 M undefined
20110 undefined-16.41 M undefined-14.04 M undefined
201030.33 M undefined3.52 M undefined1.99 M undefined
200916.3 M undefined-16.14 M undefined-15.69 M undefined
20080 undefined-33.31 M undefined-32.08 M undefined
20070 undefined-21.8 M undefined-14.48 M undefined
20060 undefined-13.06 M undefined-12.93 M undefined
20050 undefined-6.86 M undefined-6.31 M undefined
20040 undefined-2.25 M undefined-2.46 M undefined

BioLine RX Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000016300000000000004
-------87.50-------------
------62.5076.67------------25.00
00000010230000000000001
0-2-6-13-21-33-163-16-21-16-17-16-16-25-25-28-22-24-29-42
-------100.0010.00-------------1,050.00
0-2,000-6,000-12,000-14,000-32,000-15,0001,000-14,000-19,000-17,000-11,000-14,000-15,000-24,000-22,000-25,000-30,000-27,000-24,000-60,000
--200.00100.0016.67128.57-53.13-106.67-1,500.0035.71-10.53-35.2927.277.1460.00-8.3313.6420.00-10.00-11.11150.00
6.146.146.146.145.46.389.7612.4512.3616.9422.4932.4351.4156.1489.97108.6146.41252.84662.93773.96963.37
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The BioLine RX Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the BioLine RX is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
                                       
3.671.361.5450.315.9927.9839.6925.9521.4118.2434.6847.6635.6249.4830.1527.4922.5957.1451.0842.99
0000000000000000000358
0000000000000000000830
00000000000000000001.95
000.660.858.180.290.010.180.220.260.220.230.260.310.490.110.150.130.21.05
3.671.362.251.1524.1728.2739.726.1321.6318.534.947.8935.8849.7930.6427.622.7457.2651.2847.18
0.150.480.90.971.451.11.281.110.850.710.722.912.612.512.233.472.72.282.51.89
3037000960000000001,000000000
000000000000000001427210
0000.510.850.80.380.30.290.250.120.150.187.0221.9721.8921.7121.721.8914.85
00000000000000000000
0.131.941.480.940.231.30.740.7710.210.220.060.050.060.0600000
0.312.792.382.423.493.22.42.182.141.171.053.122.8410.5924.2625.3624.4124.1325.116.74
3.984.154.5853.5727.6631.4742.128.3123.7719.6735.9551.0138.7260.3854.8952.9547.1581.3976.3863.93
                                       
0.020.840.030.160.170.330.350.320.490.71.061.461.512.843.114.699.8721.0727.131.36
6.7710.8414.3779.8581.71110.72119.54110.61124.68147.08167.33196.2199.57240.68250.19265.94279.24339.35338.98355.48
-2.95-8.92-21.83-32.45-61.12-79.88-82.42-88.42-110.16-136.04-135.17-148.63-164.64-189.22-210.57-235.83-265.67-290.91-313.82-372.2
0000000000-1.42-1.42-1.42-1.42-1.42-1.42-1.42-1.42-1.42-1.42
00000000000000000000
3.842.76-7.4347.5620.7631.1737.4722.5115.0111.7431.8147.6135.0352.8841.3233.3822.0368.0950.8413.22
0.130.340.471.371.581.393.264.32001.651.912.595.524.499.077.365.576.9710.87
000001.30.820.710.740.721.251.130.961.091.35001.231.663.27
0.090.651.55.028.38.22.131.645.672.2900.010.020.020.010000.0813.05
00000000000000000000
0000000.090.080.04000.090.090.090.92.893.282.931.973.67
0.220.991.976.399.8810.896.36.756.453.012.913.143.666.726.7511.9710.649.7210.6830.85
00.683.090000.120.030000.340.250.167.847.564.41.7310.367.92
00000000000000000000
0.030.037.150000.010.022.925.291.50.2101.210.320.6610.221.864.5111.93
0.030.7110.240000.130.052.925.291.50.550.251.368.168.2214.623.5914.8619.85
0.251.712.216.399.8810.896.436.89.378.34.413.693.918.0814.9120.1925.2613.325.5450.7
4.094.464.7853.9530.6442.0643.929.3124.3820.0436.2151.338.9460.9756.2353.5747.2981.3976.3863.93
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of BioLine RX provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand BioLine RX's financial health and stability.

Assets

BioLine RX's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that BioLine RX must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of BioLine RX after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into BioLine RX's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
0-2,000-6,000-12,000-14,000-32,000-15,0001,000-14,000-19,000-17,000-11,000-14,000-15,000-24,000-22,000-25,000-30,000-27,000-24,000
00000000000000000000
00000000000000000000
0001-41-6410-30002-14-101
00013204000-50000-273-3
00000000000000001,000000
00000000000000000000
0-2-5-10-14-27-2110-11-19-19-15-14-14-20-24-22-23-23-26
00000-1000000-20-4-100000
00-200-97-7-1013-5-19-159-159516-384
00-100-78-7-1013-5-19-129-1119516-384
00000000000000000000
0002900000000009-1-3-36
0558500240015153229238320216114
056105902400151532292381319175720
--------------------
00000000000000000000
03-2045-37111-229-10-30-32-1111-3-2
-0.5-2.29-6.34-10.93-14.83-29.38-21.7710.27-12.26-19.69-19.66-15.94-16.89-14.57-24.79-34.41-22.74-23.21-23.67-26.56
00000000000000000000

BioLine RX stock margins

The BioLine RX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioLine RX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioLine RX.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BioLine RX's sales revenue. A higher gross margin percentage indicates that the BioLine RX retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BioLine RX's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BioLine RX's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioLine RX's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioLine RX. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioLine RX's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BioLine RX Margin History

BioLine RX Gross marginBioLine RX Profit marginBioLine RX EBIT marginBioLine RX Profit margin
202323.08 %-895.65 %-1,262.79 %
202223.08 %0 %0 %
202123.08 %0 %0 %
202023.08 %0 %0 %
201923.08 %0 %0 %
201823.08 %0 %0 %
201723.08 %0 %0 %
201623.08 %0 %0 %
201523.08 %0 %0 %
201423.08 %0 %0 %
201323.08 %0 %0 %
201223.08 %0 %0 %
201123.08 %0 %0 %
201077.38 %11.61 %6.56 %
200964.6 %-99.02 %-96.26 %
200823.08 %0 %0 %
200723.08 %0 %0 %
200623.08 %0 %0 %
200523.08 %0 %0 %
200423.08 %0 %0 %

BioLine RX Stock Sales Revenue, EBIT, Earnings per Share

The BioLine RX earnings per share therefore indicates how much revenue BioLine RX has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioLine RX earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioLine RX's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioLine RX’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioLine RX's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioLine RX Revenue, EBIT and net profit per share

DateBioLine RX Sales per ShareBioLine RX EBIT per shareBioLine RX Earnings per Share
20230 undefined-0.04 undefined-0.06 undefined
20220 undefined-0.04 undefined-0.03 undefined
20210 undefined-0.04 undefined-0.04 undefined
20200 undefined-0.09 undefined-0.12 undefined
20190 undefined-0.19 undefined-0.17 undefined
20180 undefined-0.24 undefined-0.21 undefined
20170 undefined-0.28 undefined-0.27 undefined
20160 undefined-0.29 undefined-0.28 undefined
20150 undefined-0.32 undefined-0.28 undefined
20140 undefined-0.53 undefined-0.34 undefined
20130 undefined-0.76 undefined-0.76 undefined
20120 undefined-1.25 undefined-1.17 undefined
20110 undefined-1.33 undefined-1.14 undefined
20102.44 undefined0.28 undefined0.16 undefined
20091.67 undefined-1.65 undefined-1.61 undefined
20080 undefined-5.22 undefined-5.03 undefined
20070 undefined-4.04 undefined-2.68 undefined
20060 undefined-2.13 undefined-2.11 undefined
20050 undefined-1.12 undefined-1.03 undefined
20040 undefined-0.37 undefined-0.4 undefined

BioLine RX business model

BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.com.

BioLine RX SWOT Analysis

Strengths

BioLine RX Ltd possesses a strong technological expertise in the field of biopharmaceuticals. This enables the company to develop innovative and effective products.

The company has a diverse pipeline of drugs in various stages of development, providing a foundation for future growth and potential revenue streams.

BioLine RX Ltd has established strategic partnerships with renowned pharmaceutical companies, allowing for collaboration and access to additional resources and expertise.

Weaknesses

One of the main weaknesses of BioLine RX Ltd is its dependency on the success of its drug candidates. If any of the candidates fail in clinical trials, it can significantly impact the company's financial performance.

The company operates in a highly competitive industry where market entry barriers are significant. This poses a challenge for BioLine RX Ltd in gaining market share and establishing a strong presence.

BioLine RX Ltd may face resource constraints due to limited financial resources, which could limit its ability to fully capitalize on market opportunities.

Opportunities

The increasing demand for innovative biopharmaceutical products presents a significant opportunity for BioLine RX Ltd to expand its market presence and generate substantial revenue.

Collaborating with academic institutions and research organizations can provide access to cutting-edge research and development capabilities, enabling the company to stay ahead of competitors.

Expanding into emerging markets with unmet medical needs can allow BioLine RX Ltd to tap into new customer segments and diversify its revenue streams.

Threats

BioLine RX Ltd operates in a heavily regulated industry, which exposes the company to compliance and legal risks. Failure to comply with regulations can lead to penalties and reputational damage.

The emergence of new market entrants and competitors with significant resources and established market presence poses a threat to BioLine RX Ltd's market share and competitiveness.

Unforeseen challenges in the development and commercialization of drug candidates, such as unexpected side effects or delays in regulatory approvals, can negatively impact the company's financial performance and reputation.

BioLine RX Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

BioLine RX historical P/E ratio, EBIT, and P/S ratio.

BioLine RX shares outstanding

The number of shares was BioLine RX in 2023 — This indicates how many shares 963.366 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BioLine RX earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BioLine RX's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BioLine RX’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BioLine RX's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BioLine RX Stock splits

In BioLine RX's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for BioLine RX.

BioLine RX latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240 -0.01  (0 %)2024 Q1
9/30/20230 -0.3  (0 %)2023 Q3
9/30/2015-0.08 -0.12  (-47.06 %)2015 Q3
1

BioLine RX list of shareholders

%
Name
Stocks
Change
Date
0.30879 % Schwartz (Aharon)3,705,0003,705,0003/16/2024
0.06817 % Dimensional Fund Advisors, L.P.817,91203/31/2024
0.02739 % Zeevi (Mali)328,665328,6653/16/2024
0.02538 % Dimensional Fund Advisors, Ltd.304,51401/31/2024
0.01433 % Serlin (Philip A)171,900171,9003/16/2024
0.00551 % Sorani (Ella)66,15066,1503/16/2024
1

Most common questions regarding BioLine RX

What values and corporate philosophy does BioLine RX represent?

BioLine RX Ltd represents values of innovation, collaboration, and commitment to improving patients' lives. The company believes in developing novel therapeutics and innovative solutions to address unmet medical needs. BioLine RX Ltd is dedicated to enhancing the quality of life for patients by advancing its diverse pipeline of potential medications. With a focus on partnerships and collaborations, BioLine RX Ltd aims to leverage its resources and expertise to bring promising therapies to market. By prioritizing patient outcomes and maintaining a patient-centric approach, BioLine RX Ltd strives to make a positive impact in the healthcare industry.

In which countries and regions is BioLine RX primarily present?

BioLine RX Ltd primarily operates in Israel, its home country. With headquarters in Modi'in, the company focuses on developing and commercializing novel therapeutics for various medical fields. Primarily present in Israel, BioLine RX Ltd leverages its expertise and collaborates with global partners to advance its pipeline and enhance the potential for successful treatments. By concentrating on its domestic market and fostering international collaborations, BioLine RX Ltd aims to deliver innovative solutions and contribute to improving global healthcare outcomes.

What significant milestones has the company BioLine RX achieved?

BioLine RX Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 2 clinical trial for its BL-8040 drug, demonstrating its potential as a treatment for acute myeloid leukemia (AML) and other hematological malignancies. Furthermore, BioLine RX Ltd has advanced its promising product pipeline, including the initiation of various clinical trials and collaborations with renowned research institutions. The company's commitment to innovation and dedication to improving patient outcomes have positioned BioLine RX Ltd as a key player in the biopharmaceutical industry, with great potential for growth and success in the future.

What is the history and background of the company BioLine RX?

BioLine RX Ltd is a renowned biopharmaceutical company specializing in the development of novel therapeutics. Established in 2003, BioLine RX has been dedicated to advancing innovative drugs for various medical conditions. The company focuses on identifying promising research and forming strategic collaborations to bring effective treatments to the market. With a strong pipeline of potential therapies, BioLine RX aims to address unmet medical needs in areas such as oncology, immunology, and more. Committed to making a significant impact on patients' lives, BioLine RX continues to be a key player in the biopharmaceutical industry.

Who are the main competitors of BioLine RX in the market?

The main competitors of BioLine RX Ltd in the market include companies such as Pfizer Inc., Merck & Co., Inc., Novartis International AG, and Moderna, Inc.

In which industries is BioLine RX primarily active?

BioLine RX Ltd is primarily active in the biotechnology and pharmaceutical industries. They specialize in developing and commercializing novel drugs for various medical conditions. With a focus on oncology, immunology, and infectious diseases, BioLine RX Ltd aims to provide innovative and effective therapeutic solutions. Through their extensive research and development efforts, they strive to improve patient outcomes and address unmet medical needs. As a reputable player in the biotech and pharmaceutical sectors, BioLine RX Ltd continues to drive advancements in healthcare with its cutting-edge drug development pipeline.

What is the business model of BioLine RX?

BioLine RX Ltd is a biopharmaceutical company focused on the development and commercialization of novel therapeutics. Their business model revolves around identifying promising technologies and advancing them through preclinical and clinical stages. By collaborating with leading academic institutions and strategic partners, BioLine RX aims to generate a diverse and innovative pipeline of products targeting unmet medical needs. This Israeli-based company is committed to leveraging its expertise in drug development and strategic relationships to bring novel therapeutics to market, thereby improving patients' lives and delivering value to its shareholders.

What is the P/E ratio of BioLine RX 2024?

The P/E ratio cannot be calculated for BioLine RX at the moment.

What is the P/S ratio of BioLine RX 2024?

The P/S cannot be calculated for BioLine RX currently.

What is the AlleAktien quality score of BioLine RX?

The AlleAktien quality score for BioLine RX is 4/10.

What is the revenue of BioLine RX 2024?

The revenue cannot currently be calculated for BioLine RX.

How high is the profit of BioLine RX 2024?

The profit cannot currently be calculated for BioLine RX.

What is the business model of BioLine RX

BioLine RX Ltd. is an emerging biotechnology company specializing in the development and commercialization of novel therapeutic approaches for severe diseases. The company was founded in 2003 and is headquartered in Jerusalem, Israel. It has experienced significant growth in recent years and is currently listed on the NASDAQ and the Tel Aviv Stock Exchange. BioLine RX is divided into various business segments focused on the development and commercialization of innovative therapeutic approaches. The first area is clinical research, which is focused on developing drugs for the treatment of cancer, autoimmune diseases, and inflammatory diseases such as diabetes and rheumatism. The second area of the company is preclinical research, which focuses on the identification and validation of novel compounds and targets. In addition to these two core areas, BioLine RX also engages in partnerships with other companies and institutions to create synergies and collaborations in the development of new therapeutic approaches. BioLine RX has developed a range of products and therapeutic approaches based on novel technologies. One important product is BL-8040, a fusion protein aimed at the treatment of leukemia and other types of cancer. BL-8040 works by selectively recognizing tumor cells and inducing programmed cell death (apoptosis). The effectiveness of BL-8040 has been demonstrated in various phase 2 studies on patients, and BioLine RX plans to conduct further clinical trials to evaluate the efficacy of the drug. Another important product is BL-7010, a polymer developed as a treatment for celiac disease. Celiac disease is an autoimmune disorder that leads to inflammation of the small intestine and is triggered by gluten. BL-7010 works by binding gluten molecules in the intestine, thereby preventing the initiation of an immune reaction. The effectiveness of BL-7010 has been demonstrated in preclinical studies and in a phase 1 study on healthy volunteers, and BioLine RX plans to conduct further clinical trials to evaluate the efficacy of the drug. To promote the commercialization of its products and therapeutic approaches, BioLine RX has entered into partnerships with various companies and institutions. One important partnership is the collaboration with Novartis, a leading company in the pharmaceutical industry. Under this partnership, BioLine RX works with Novartis to develop and commercialize new cancer drugs. Overall, BioLine RX has developed a promising business model based on the research and commercialization of novel therapeutic approaches. With a strong focus on clinical and preclinical research, as well as partnerships with other companies and institutions, BioLine RX is expected to continue to be a major player in the biotechnology industry.

What is the BioLine RX dividend?

BioLine RX pays a dividend of 0 USD distributed over payouts per year.

How often does BioLine RX pay dividends?

The dividend cannot currently be calculated for BioLine RX or the company does not pay out a dividend.

What is the BioLine RX ISIN?

The ISIN of BioLine RX is IL0011015182.

What is the BioLine RX ticker?

The ticker of BioLine RX is BLRX.TA.

How much dividend does BioLine RX pay?

Over the past 12 months, BioLine RX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioLine RX is expected to pay a dividend of 0 USD.

What is the dividend yield of BioLine RX?

The current dividend yield of BioLine RX is .

When does BioLine RX pay dividends?

BioLine RX pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioLine RX?

BioLine RX paid dividends every year for the past 0 years.

What is the dividend of BioLine RX?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioLine RX located?

BioLine RX is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioLine RX kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioLine RX from 9/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did BioLine RX pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of BioLine RX in the year 2023?

In the year 2023, BioLine RX distributed 0 USD as dividends.

In which currency does BioLine RX pay out the dividend?

The dividends of BioLine RX are distributed in USD.

All fundamentals about BioLine RX

Our stock analysis for BioLine RX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLine RX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.